1. Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group

   • Peter L. Bonate
   • Malidi Ahamadi
   • Janet R. Wade

   Commentary 02 February 2016 Pages: 123 - 135

   

2. A strategy for residual error modeling incorporating scedasticity of variance and distribution shape

   • Anne-Gaëlle Dosne
   • Martin Bergstrand
   • Mats O. Karlsson

   Original Paper Open access 17 December 2015 Pages: 137 - 151

   

3. Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects

   • Rashmi Mehta
   • Michelle Green
   • Jonathan Wagg

   Original Paper 06 January 2016 Pages: 153 - 164

   

4. Determination of a suitable voriconazole pharmacokinetic model for personalised dosing

   • David A. J. McDougall
   • Jennifer Martin
   • Bruce Green

   Original Paper 16 December 2015 Pages: 165 - 177

   

5. Organ data from the developing Göttingen minipig: first steps towards a juvenile PBPK model

   • Els Van Peer
   • Noel Downes
   • Steven Van Cruchten

   Original Paper 19 December 2015 Pages: 179 - 190

   

6. Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data

   • Alanna S. Ocampo-Pelland
   • Marc R. Gastonguay
   • Matthew M. Riggs

   Original Paper 12 February 2016 Pages: 191 - 206

   

7. Input estimation for drug discovery using optimal control and Markov chain Monte Carlo approaches

   • Magnus Trägårdh
   • Michael J. Chappell
   • Peter Gennemark

   Original Paper Open access 01 March 2016 Pages: 207 - 221

   

8. Accelerating Monte Carlo power studies through parametric power estimation

   • Sebastian Ueckert
   • Mats O. Karlsson
   • Andrew C. Hooker

   Original Paper Open access 02 March 2016 Pages: 223 - 234